MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. MoonLake’s communications to investors about its VELA-2 clinical trial were overly optimistic until September 29, 2025, when it announced that "intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%." Based on this news, MoonLake shares suffered a 90% decline in value.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.